Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with government health insurance in Syria between 2018 and 2019: a retrospective analysis

Table 3 Outpatient dispensing rates of diabetes medicines according to the pharmacological subgroup (ATC3) including insulin (ATC5)

Therapeutic subgroup (ATC3)	DID^a		Patients
Therapeutic subgroup (ATC3)	n	%	n	%
Insulin and analogues (A10A)	0.96	0.16	117	0.14
Blood glucose lowering drugs excluding insulins (A10B)	34.70	5.87	4413	5.43
Total	35.66	6.03	4466^b	5.49^b
Medicine (ATC5)	DID^a		Patients
Medicine (ATC5)	n	%	n	%
Insulin (human) intermediate- or long-acting combined with fast-acting (A10AD01)	0.55	0.09	67	0.08
Insulin aspart (A10AD05)	0.18	0.03	25	0.03
Insulin (human) fast acting (A10AB01)	0.09	0.02	10	0.01
Insulin lispro (A10AD04)	0.08	0.01	12	0.01
Insulin glargine (A10AE04)	0.04	0.01	9	0.01
Insulin (human) intermediate acting (A10AC01)	0.02	0.004	4	0.005
Total	0.96	0.16	117^b	0.14^b

^aDispensing rates of diabetes medicines including insulin are expressed as the number of defined daily doses per 1000 people per day (DID)
^bSome patients dispensed different diabetes medicines. To avoid counting these patients more than once, we considered the identical number for each patient while calculating the total number and percentage of patients

ISSN: 1472-6963